ATHIRA PHARMA, INC.

Analyst Reco. Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
1.96 ^USD	0.00%		+2.08%	-19.34%

Apr. 15	Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	CI
Apr. 11	Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Adjusts Athira Pharma Price Target to $19 From $20, Maintains Market Outperform Rating	23-08-11	MT
Mizuho Cuts Price Target on Athira Pharma to $5 From $6, Reiterates Buy Rating	23-05-15	MT
BTIG Adjusts Price Target on Athira Pharma to $10 From $33, Maintains Buy Rating	23-03-30	MT
JMP Securities Upgrades Athira Pharma to Market Outperform From Market Perform; Price Target is $20	22-10-18	MT
Mizuho Securities Initiates Athira Pharma at Buy with $6 Price Target	22-07-07	MT
Mizuho Initiates Athira Pharma With Buy Rating, $6 Price Target, Potentially 'Mis-Priced' Stock	22-07-06	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
Goldman Sachs Adjusts Price Target for Athira Pharma to $3 From $11, Maintains Neutral Rating	22-06-23	MT
Stifel Nicolaus Downgrades Athira Pharma to Hold From Buy, Adjusts Price Target to $5 From $36	22-06-23	MT
JMP Securities Downgrades Athira Pharma to Market Perform From Market Outperform	22-06-23	MT
Jefferies Downgrades Athira Pharma to Hold From Buy, Adjusts Price Target to $3 From $32	22-06-23	MT
BTIG Starts Athira Pharma at Buy With $33 Price Target	22-05-10	MT
Berenberg Bank Initiates Coverage on Athira Pharma With Buy Rating, $33 Price Target	22-04-21	MT
Goldman Sachs Reinstates Athira Pharma at Neutral With $16 Price Target	21-12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer